Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 14, Issue 10, Pages 1097-1100Publisher
EXPERT REVIEWS
DOI: 10.1586/14737140.2014.940329
Keywords
AML; cancer prevention; HDAC; MDS; methylation; valproic acid
Categories
Funding
- NCI NIH HHS [5 P50 CA128613-02, P50 CA128613] Funding Source: Medline
- BLRD VA [IK2 BX001283] Funding Source: Medline
Ask authors/readers for more resources
Valproic acid is an inhibitor of class I histone deacetylases. Epigenetic therapies in cancer have been focus of a keen interest and histone deacetylase inhibitors, in particular, have been approved for certain types of hematologic malignancies. Valproic acid is an attractive candidate for cancer therapy due to its mechanism of action, its low cost and generally good clinical tolerability. In the following editorial, we will review its role as monotherapy for cancer, its place in combination epigenetic therapy, and its role as chemosensitizer, and cancer preventative agent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available